Billionaire Gerald Chan Bets Early On Chinese Biotech
This article was originally published in Start Up
You may also be interested in...
NEW YORK - Perhaps the largest hurdle China Medical City faces with a U.S. audience is explaining how it differs from China's more established science and technology parks like Zhangjiang Hi Tech Park in Shanghai, Zhong-guan-cun Life Science Park in Beijing and BioBay in Suzhou
In the latest and most ambitious attempt to create a new global pharma with one foot in China and one in the West, Ascletis Inc. has launched with a hybrid drug development model that has attracted $100 million in committed funding.
With the launch of AAVLife, Versant Ventures adds to its gene therapy portfolio, and people with Friedreich's ataxia can look to another program that takes aim at the rare inherited disease.